Silence Therapeutics plc (SLN)

23,22 -0,69 (-2,89%) Börsenschluss: 04:00PM EDT

Silence Therapeutics plc

72 Hammersmith Road
London W14 8TH
United Kingdom
44 20 3457 6900
https://www.silence-therapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 109

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Craig A. Tooman M.B.A.	President, CEO & Executive Director	1,49M	N/A	1965
Ms. Rhonda L. Hellums	CFO & Secretary	907,23k	N/A	1973
Dr. Steven J. Romano M.D.	Head of Research & Development	662,65k	N/A	1959
Dr. Marie Wikstrom Lindholm Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Gem Gokmen Hopkins	Head of IR & Corporate Communications	N/A	N/A	N/A
Dr. Barbara A. Ruskin J.D., Ph.D.	Senior VP and Chief Intellectual Property & Innovation Officer	N/A	N/A	1961
Dr. Eric Floyd M.B.A., M.S., Ph.D.	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	1963
Mr. J.P. Gabriel	Chief Technical Operations Officer	N/A	N/A	N/A
Mr. Curtis Rambaran M.D.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Corporate Governance

Silence Therapeutics plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.